For more than 2 decades, we've been working diligently to develop medicine for people living with chronic myeloid leukemia (#CML). This FDA approval reflects our ongoing commitment to that community.
#ReimaginingMedicine
Earlier this year, Novartis and @themaxfndn launched CancerPath to Care to provide access to #cancer therapies. On Tuesday, we expanded access to chronic myeloid leukemia (#CML) treatment for patients in 36 LMICs. We are proud to continue our partnership with The Max Foundation.